Quick Answer
Pasithea Therapeutics Corp. reported Operating Income of -$20.86 million for fiscal year 2025.
Pasithea Therapeutics Corp. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$20.86M | -46.4% |
| 2024 | -$14.25M | +10.8% |
| 2023 | -$15.98M | -26.9% |
| 2022 | -$12.59M | -179.3% |
| 2021 | -$4.51M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.11M | -3.5% | +18.4% |
| June 30, 2025 | -$3.81M | +3.4% | -3.6% |
| March 31, 2025 | -$3.68M | +8.9% | -22.5% |
| September 30, 2024 | -$3.00M | +20.7% | +23.8% |
| June 30, 2024 | -$3.95M | -3.0% | +2.4% |
| March 31, 2024 | -$4.04M | -25.8% | -6.6% |
| September 30, 2023 | -$3.79M | +1.7% | +1.0% |
| June 30, 2023 | -$3.83M | -46.6% | -19.2% |
- Pasithea Therapeutics Corp. showed a decrease of -46.4% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Pasithea Therapeutics Corp.’s operating income has declined by 362.7% (from -$4.51 million to -$20.86 million).
- The most recent figure is from Pasithea Therapeutics Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: